Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Roth Capital Reiterates Buy On Sarepta Following Appointment Of New Interim Chairman http://www.smarteranalyst.com/2014/08/01/roth-capital-reiterates-buy-on-sarepta-following-appointment-of-new-interim-chairman/
We Believe Pharmacyclics Shares Are Positioned For Growth, Says Roth Capital http://www.smarteranalyst.com/2014/08/01/we-believe-pharmacyclics-shares-are-positioned-for-growth-says-roth-capital/
Roth Capital Maintains Buy On Skullcandy Following 2Q14 And Full Year EPS Guidance http://www.smarteranalyst.com/2014/08/01/roth-capital-maintains-buy-on-skullcandy-following-2q14-and-full-year-eps-guidance/
Roth Capital Maintains Neutral On Pacific Sunwear Following Second Quarter Guidance http://www.smarteranalyst.com/2014/08/01/roth-capital-maintains-neutral-on-pacific-sunwear-following-second-quarter-guidance/
Maxwell Technologies: We May Have Been An Inning Or Two Too Early, Says Roth Capital http://www.smarteranalyst.com/2014/08/01/maxwell-technologies-we-may-have-been-an-inning-or-two-too-early-says-roth-capital/
$EXPE Cantor Remains Constructive On Expedia Following 2Q14 Results; Raises PT To $92 http://www.smarteranalyst.com/2014/08/01/cantor-remains-constructive-on-expedia-following-2q14-results-raises-pt-to-92/
$EXPE Cantor Remains Constructive On Expedia Following 2Q14 Results; Raises PT To $92 http://www.smarteranalyst.com/2014/08/01/cantor-remains-constructive-on-expedia-following-2q14-results-raises-pt-to-92/
$LNKD Topeka Capital Reiterates Buy On LinkedIn Following 2Q14 Earnings Results http://www.smarteranalyst.com/2014/08/01/topeka-capital-reiterates-buy-on-linkedin-following-2q14-earnings-results/
$LNKD Topeka Capital Reiterates Buy On LinkedIn Following 2Q14 Earnings Results http://www.smarteranalyst.com/2014/08/01/topeka-capital-reiterates-buy-on-linkedin-following-2q14-earnings-results/
$LNKD Topeka Capital Reiterates Buy On LinkedIn Following 2Q14 Earnings Results http://www.smarteranalyst.com/2014/08/01/topeka-capital-reiterates-buy-on-linkedin-following-2q14-earnings-results/
$LNKD Topeka Capital Reiterates Buy On LinkedIn Following 2Q14 Earnings Results http://www.smarteranalyst.com/2014/08/01/topeka-capital-reiterates-buy-on-linkedin-following-2q14-earnings-results/
$LNKD Topeka Capital Reiterates Buy On LinkedIn Following 2Q14 Earnings Results http://www.smarteranalyst.com/2014/08/01/topeka-capital-reiterates-buy-on-linkedin-following-2q14-earnings-results/
Topeka Capital Reiterates Buy On LinkedIn Following 2Q14 Earnings Results http://www.smarteranalyst.com/2014/08/01/topeka-capital-reiterates-buy-on-linkedin-following-2q14-earnings-results/
William Blair Reaffirms A Market Perform On Eaton Following 2Q14 Results, Reduces PT To $68 http://www.smarteranalyst.com/2014/07/30/william-blair-reaffirms-a-market-perform-on-eaton-following-2q14-results-reduced-pt-to-68/
$GNC GNC Holdings: Investors Should Avoid Shares Given Incremental Downside Risk, Says William Blair http://www.smarteranalyst.com/2014/07/30/gnc-holdings-investors-should-avoid-shares-given-incremental-downside-risk-says-william-blair/
Canaccord Maintains Buy On Level 3 Communications Following Solid 2Q14 Results http://www.smarteranalyst.com/2014/07/30/canaccord-maintains-buy-on-level-3-communications-following-solid-2q14-results/
National Oilwell Varco Remains Our Preferred Large-Cap Investment Idea, Says William Blair http://www.smarteranalyst.com/2014/07/30/national-oilwell-varco-remains-our-preferred-large-cap-investment-idea-says-william-blair/
Canaccord Reiterates Buy On Range Resources Following 2Q14 Results http://www.smarteranalyst.com/2014/07/30/canaccord-reiterates-buy-on-range-resources-following-2q14-results/
$SLCA William Blair Maintains Outperform On US Silica Following Strong Quarter Results http://www.smarteranalyst.com/2014/07/30/william-blair-maintains-outperform-on-us-silica-following-strong-quarter-results/
William Blair Maintains Outperform On US Silica Following Strong Quarter Results http://www.smarteranalyst.com/2014/07/30/william-blair-maintains-outperform-on-us-silica-following-strong-quarter-results/
$TWTR Cantor Fitzgerald Maintains Buy On Twitter Following Booming 2Q14 Earnings http://www.smarteranalyst.com/2014/07/30/cantor-fitzgerald-maintains-buy-on-twitter-following-booming-2q14-earnings/
$TWTR Cantor Fitzgerald Maintains Buy On Twitter Following Booming 2Q14 Earnings http://www.smarteranalyst.com/2014/07/30/cantor-fitzgerald-maintains-buy-on-twitter-following-booming-2q14-earnings/
$TWTR Cantor Fitzgerald Maintains Buy On Twitter Following Booming 2Q14 Earnings http://www.smarteranalyst.com/2014/07/30/cantor-fitzgerald-maintains-buy-on-twitter-following-booming-2q14-earnings/
Cantor Fitzgerald Maintains Buy On Twitter Following Booming 2Q14 Earnings
$KBIO William Blair Reaffirms Outperform On KaloBios As Sanofi Returns Global Rights To KB001-A http://www.smarteranalyst.com/2014/07/29/william-blair-reaffirms-outperform-on-kalobios-as-sanofi-returns-global-rights-to-kb001-a/
$ACRX Unclear If AcelRx Can Address Optical Errors For Zalviso Without Clinical Work, Says Canaccord http://www.smarteranalyst.com/2014/07/29/unclear-if-acelrx-can-address-optical-errors-for-zalviso-without-clinical-work-says-canaccord/
$PCYC Roth Capital Reiterates Buy On Pharmacyclics In Light Of Recent FDA Approval For Imbruvica http://www.smarteranalyst.com/2014/07/29/roth-capital-reiterates-buy-on-pharmacyclics-in-light-of-recent-fda-approval-for-imbruvica/
$RNA Roth Capital Upgrades Prosena To Buy, Sees %175 Upside For The Stock http://www.smarteranalyst.com/2014/07/29/roth-capital-upgrades-prosena-to-buy-sees-5-upside-for-the-stock/
$RNA Roth Capital Upgrades Prosena To Buy, Sees %175 Upside For The Stock http://www.smarteranalyst.com/2014/07/29/roth-capital-upgrades-prosena-to-buy-sees-5-upside-for-the-stock/
Roth Capital Reiterates Buy On Stemline Following Initiation Of Clinical Development Program http://www.smarteranalyst.com/2014/07/28/roth-capital-reiterates-buy-on-stemline-following-initiation-of-clinical-development-program/
Roth Capital Affirms Buy On AcelRx Pharmaceuticals Despite FDA Rejection http://www.smarteranalyst.com/2014/07/28/roth-capital-affirms-buy-on-acelrx-pharmaceuticals-despite-fda-rejections/
$ACRX Roth Capital Affirms Buy On AcelRx Pharmaceuticals Despite FDA Rejection http://www.smarteranalyst.com/2014/07/28/roth-capital-affirms-buy-on-acelrx-pharmaceuticals-despite-fda-rejections/
$EDAP EDAP: Ablatherm Has A 65-70% Chance Of A Positive Panel Vote, Says H.C. Wainwright http://www.smarteranalyst.com/2014/07/28/edap-ablatherm-has-a-65-70-chance-of-a-positive-panel-vote-says-h-c-wainwrightin/
$XGTI XG Technology: We Recommend Investors Remain On Sidelines, Says Feltl And Company http://www.smarteranalyst.com/2014/07/28/xg-technology-we-recommend-investors-remain-on-sidelines-says-feltl-and-company/
$SODA Roth Capital Reiterates Buy On SodaStream Amid Expectations Of Strong 2H http://www.smarteranalyst.com/2014/07/28/roth-capital-reiterates-buy-on-sodastream-amid-expectations-of-strong-2h/
$SODA Roth Capital Reiterates Buy On SodaStream Amid Expectations Of Strong 2H http://www.smarteranalyst.com/2014/07/28/roth-capital-reiterates-buy-on-sodastream-amid-expectations-of-strong-2h/
Roth Capital Reiterates Buy On SodaStream Amid Expectations Of Strong 2H http://www.smarteranalyst.com/2014/07/28/roth-capital-reiterates-buy-on-sodastream-amid-expectations-of-strong-2h/
$ACRX Cowen Maintains An Outperform On AcelRx As FDA Issues CRL For Zalviso’s NDA http://www.smarteranalyst.com/2014/07/28/cowen-maintains-an-outperform-on-acelrx-as-fda-issues-crl-for-zalvisos-nda/
William Blair Maintains Outperform On Pandora Media Following 2Q14 Results http://www.smarteranalyst.com/2014/07/25/william-blair-maintains-outperform-on-pandora-media-following-2q14-results/